Our model derives from an extensive literature review and interviews with health care providers, representing an integration of critical race theory, social cognition theory, and the empirical literatures on clinical decision making, provider behavior, and the role of genetics and genomics in complex disease risk [ 1, 22, 25– 35].
In clinical decision making, providers should consider not only the efficacy of second generation antidepressants and cognitive behavioral therapy interventions but also patients' preferences about potential adverse events, the costs and availability of each treatment, and expected treatment effects.
Specifically, technologies that support patient decision-making, provider decision support, and patient-provider communication.
4) Interpreting Difficulties: Because of impairment of individual learning and decision-making, providers are unable to generate accurate judgments about what is happening with their practices and what, if any, changes should occur.
Although there has been progression in the development of ICT guided tools and these tools have become practical equipment for enhanced decision making, healthcare providers still experience great barriers in using and implementing them for several, often unclear reasons [ 33, 34].
Electronic medical records (EMRs) can benefit patient care in a number of ways, including enabling timely access to patient information, supporting informed clinical decision-making, improving provider-provider and provider-patient communication and reducing health care costs [ 1- 4].
Predicting the progression of chronic kidney disease (CKD) is vital for clinical decision making and patient-provider communication.
Moreover, the distance between the distant HC and the referral hospital easily lead to different decision making between the providers at distant and non-distant health centers.
Nearly all stakeholders involved in health-related decision making, including healthcare providers, patients, managers and policymakers, in developed and developing countries, have faced such challenges [ 2].
Although this finding relates to decision making amongst care providers, it has significant repercussions for the type of care women receive and the amount of support they are given to enable autonomous decision making.
Cost effectiveness studies of PD therapeutic interventions are therefore essential to help the decision making of care providers, affected individuals and their families, and policy makers, and also for predicting alternative interventions.
